|
Patient and physician perceptions about blood transfusions in the myelodysplastic syndromes |
Jul 2020 |
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
|
Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions |
Jul 2020 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
Venetoclax and Hypomethylating Agents (HMAs) Induce High Response Rates in MDS, Including Patients After HMA Therapy Failure |
Jul 2020 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse |
Jul 2020 |
Blood Advances |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients |
Jul 2020 |
Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Targeting the Microenvironment in MDS: The Final Frontier |
Jul 2020 |
Frontiers in Pharmacology |
Myelodysplastic Syndromes (MDS) |
|
Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International PNH Registry |
Jul 2020 |
European Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Kinetics of Pre-Myelodysplastic Syndromes Blood Values Correlate with Disease Risk and Survival |
Jul 2020 |
Hematological Oncology |
Myelodysplastic Syndromes (MDS) |
|
High-dose Romiplostim Accelerates Hematologic Recovery in Patients With Aplastic Anemia Refractory to Eltrombopag |
Jul 2020 |
Leukemia |
Aplastic Anemia |
|
Genetics of Progression From MDS to Secondary Leukemia |
Jul 2020 |
Blood |
Myelodysplastic Syndromes (MDS) |
